In GATHER2 open-label extension study, IZERVAY reduced GA growth 37-40.5% vs. projected sham, with earlier intervention resulting in greater protection of retinal tissue area Study results found no ...
NORTHBROOK, Ill., March 26, 2024 /PRNewswire/ -- Iveric Bio, An Astellas Company (TSE: 4503, President and CEO: Naoki Okamura, "Astellas"), today announced the U.S. Centers for Medicare and Medicaid ...
Over 2 years, only a slight increased incidence of choroidal neovascularization was observed for IZERVAY pooled vs. sham; in year 2, incidence of CNV was similar for IZERVAY EOM vs. sham "GA is a ...
TOKYO, Feb. 12, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the U.S. Food and Drug Administration (FDA) approved expanded U.S.
*Intended for U.S. Audiences only. Whether it was a weekend getaway to Chicago to see a play or snapping pics of Big Ben in London, going on adventures was always a highlight for Jan,* a 56 year-old ...
"Geographic atrophy is a progressive disease that can lead to irreversible vision loss and early treatment can have a significant impact on patients' lives. Receiving a permanent J-code in the U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results